Divi's laboratories Limited has officially notified stock exchanges about an upcoming board meeting scheduled to review and approve its third-quarter financial performance for fiscal year 2026. The pharmaceutical company has communicated this development to both major Indian stock exchanges as part of its regulatory compliance obligations.

Board Meeting Details

The company has provided specific information regarding the scheduled board meeting and its agenda:

Regulatory Compliance and Trading Window

The board meeting announcement follows strict adherence to SEBI regulations, specifically Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates listed companies to inform stock exchanges about board meetings where financial results will be considered.

The company has implemented a trading window closure as part of its insider trading prevention measures. The trading window restrictions are structured as follows:

• Closure Start Date: January 01, 2026
• Closure End Date: February 13, 2026
• Duration: Until 48 hours after financial results declaration
• Previous Intimation: December 31, 2025

Stock Exchange Communication

Divi's Laboratories has formally communicated this development to both the National Stock Exchange of India Limited and BSE Limited. The company trades under the symbol DIVISLAB on NSE and carries scrip code 532488 on BSE. The notification was signed by M. Satish Choudhury, Company Secretary & Compliance Officer, ensuring proper authorization and compliance with corporate governance standards.

Expected Timeline

The February 11, 2026 board meeting will focus on reviewing the company's performance for the third quarter of fiscal year 2026, covering the period ending December 31, 2025. Following the board's approval, the financial results are expected to be declared, after which normal trading activities will resume 48 hours later on February 13, 2026.

Divis Laboratories reported robust export performance in December, with shipments reaching $117.00 million, marking a significant 49.00% growth compared to the previous month. This strong performance demonstrates the pharmaceutical company's expanding international market presence and growing global demand for its products.

December Export Performance

The company's December export data reflects substantial momentum in its international business operations. The following table summarizes the key performance metrics:

Market Position Strengthening

The 49.00% month-on-month increase in export shipments indicates strong demand for Divis Laboratories' pharmaceutical products in international markets. This performance suggests the company's continued success in maintaining and expanding its global customer base while effectively meeting international quality and delivery requirements.

The $117.00 million export figure represents a significant milestone for the company's international operations, reflecting both operational efficiency and market competitiveness in the global pharmaceutical sector. This growth trajectory demonstrates the company's ability to capitalize on international opportunities and maintain strong relationships with overseas clients.